Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
|Articles|November 18, 2022
Infectious Disease Update: This Week's Top Stories
Author(s)Nina Cosdon
Read and watch the infectious disease trial data shared this week.
Advertisement
1.
Young women who binge drink, and especially those who use multiple substances, had a higher risk of COVID-19 infection and mental health complications.
ICU specialist, Christian Sandrock, MD, MPH, FCCP, talks about his criteria and the treatment protocols for these challenging hospital-acquired bacterial pneumonia (HABP) and ventilator-acquired bacterial pneumonia (VABP) cases.
3.
Concerns of injectable HIV PrEP safety and efficacy demonstrate a need for health care providers to share reliable information with at-risk populations.
4.
Safety profile in this study showed the frequency of adverse reactions with these boosters were similar or lower than that of either a second or third dose of the original vaccine.
5.
Dr. Tosin Goje explains the promise of ibrexafungerp for clearing yeast infection and improving quality of life for these patients.
Advertisement
Related to this article
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
In a national survey of 959 US adults, 27.9% said they had exaggerated or made up symptoms to obtain antibiotics, most often cold-like symptoms, with implications for outpatient stewardship.
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Advertisement
Advertisement
Trending on Contagion Live
1
Washington State Reports First US Avian Influenza Death of 2026
2
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
3
Cefiderocol Activity Improves in Physiologic Media, Synergizes With LL-37
4
FDA Approves Voceryq, First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis
5